Alves K, Kouassi A, Plested JS, Kalkeri R, et al. Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study. Vaccine 2025;55:127046.
PMID: 40184816